Telomir Pharmaceuticals, Inc. Financing Cash Flow
Telomir Pharmaceuticals, Inc. (TELO) reported Financing Cash Flow of $669.46 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Telomir Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $622.11K.
- Telomir Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $47.35K.
- Telomir Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $1.16M, a 11.71% increase year-over-year.
- Telomir Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $7.50M.
- Telomir Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $9.71M, a 53.25% increase from fiscal 2024.
- Telomir Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $6.34M, a 64.14% increase from fiscal 2023.
- Telomir Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $3.86M, a 721.05% increase from fiscal 2022.
- Telomir Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $470.08K.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $622.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $669.46K 10-Q · filed 2026-08-13 | $1.83M derived: sum of 3 quarters · filed 2026-08-13 | $9.33M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $47.35K 10-Q · filed 2026-05-14 | $1.21M derived: sum of 2 quarters · filed 2026-05-14 | $8.71M derived: sum of 3 quarters · filed 2026-05-14 | |
| 2025-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $8.66M derived: sum of 2 quarters · filed 2026-03-17 | $9.71M 10-K · filed 2026-03-17 | |
| 2025-09-30 | $7.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $8.55M 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | $1.05M 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $990.39K derived: sum of 2 quarters · filed 2026-03-17 | $1.12M derived: sum of 3 quarters · filed 2026-03-17 | $6.34M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$46.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $85.53K derived: sum of 2 quarters · filed 2025-11-10 | $5.30M 10-Q · filed 2025-11-10 | $6.38M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $132.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $5.34M 10-Q · filed 2025-08-14 | $6.43M derived: sum of 3 quarters · filed 2025-08-14 | $8.42M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $5.21M 10-Q · filed 2025-05-14 | $6.30M derived: sum of 2 quarters · filed 2025-05-14 | $8.29M derived: sum of 3 quarters · filed 2025-05-14 | $8.34M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-04 | $3.08M derived: sum of 2 quarters · filed 2025-02-04 | $3.12M derived: sum of 3 quarters · filed 2025-02-04 | $3.86M 10-K · filed 2025-02-04 |
| 2023-09-30 | $1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.04M derived: sum of 2 quarters · filed 2024-11-12 | $2.77M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $46.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $782.53K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $736.13K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $470.08K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |